Teacher Retirement System of Texas Has $319,000 Stock Holdings in CareDx, Inc (NASDAQ:CDNA)

Teacher Retirement System of Texas increased its position in CareDx, Inc (NASDAQ:CDNA) by 19.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,878 shares of the company’s stock after purchasing an additional 2,442 shares during the quarter. Teacher Retirement System of Texas’ holdings in CareDx were worth $319,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FMR LLC increased its holdings in CareDx by 802.4% in the third quarter. FMR LLC now owns 625,550 shares of the company’s stock valued at $19,533,000 after purchasing an additional 556,230 shares during the last quarter. Lord Abbett & CO. LLC bought a new stake in shares of CareDx in the 3rd quarter valued at about $10,873,000. Point72 Asset Management L.P. acquired a new stake in shares of CareDx in the 3rd quarter valued at approximately $8,012,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in CareDx by 25.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 875,197 shares of the company’s stock worth $18,738,000 after acquiring an additional 178,304 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in CareDx during the fourth quarter valued at approximately $3,694,000.

Analysts Set New Price Targets

Several research firms have weighed in on CDNA. Stephens reiterated an “overweight” rating and set a $40.00 target price on shares of CareDx in a report on Thursday, February 27th. HC Wainwright cut their price objective on CareDx from $26.00 to $25.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. Wells Fargo & Company raised CareDx from an “underweight” rating to an “equal weight” rating and lowered their target price for the stock from $28.00 to $24.00 in a research note on Wednesday, January 15th. Finally, StockNews.com raised shares of CareDx from a “hold” rating to a “buy” rating in a research note on Wednesday, February 26th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, CareDx has a consensus rating of “Moderate Buy” and an average target price of $31.83.

CareDx Trading Down 0.3 %

NASDAQ:CDNA opened at $17.70 on Wednesday. The firm has a fifty day simple moving average of $21.22 and a 200 day simple moving average of $23.44. CareDx, Inc has a 1-year low of $7.42 and a 1-year high of $34.84. The stock has a market capitalization of $981.04 million, a PE ratio of -6.56 and a beta of 1.95.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $1.51 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $1.46. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The company had revenue of $86.58 million during the quarter, compared to the consensus estimate of $84.56 million. On average, equities analysts predict that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.